Riskpilot← Back to searchSign inGet full accessHJEMMELEGENE AS
ASActiveOrg 918605878Dronning Eufemias Gate 16, 0191 OsloGeneral medical practice activities · NACE 8621Est. 201756 employeeshjemmelegene.no
Revenue 2024
NOK 22,6M
-3% vs 2023
EBITDA margin
-37.9%
+57% vs 2023
Equity ratio
38.9%
Financial strength
Net profit 2024
NOK -10,6M
+53% vs 2023
| Revenue | NOK 22,6M | -3% |
| EBITDA | NOK -8,6M | +57% |
| Net profit | NOK -10,6M | +53% |
| Total assets | NOK 8,5M | -46% |
| Equity | NOK 3,3M | +125% |
| Employees | 56 | — |
Legal name
HJEMMELEGENE AS
Org number
918605878
Legal form
Aksjeselskap
NACE code
8621 · General medical practice activities
Founded
28. februar 2017
Share capital
NOK 1 277 685
Employees
56 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Formidling og utvikling av digitale helsetjenester.
Address
Dronning Eufemias Gate 16, 0191 Oslo
Email
hei@hjemmelegene.no
Website
hjemmelegene.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 19 755 | 40 791 | 24 090 | 23 183 | 22 570 |
| Staff expenses | −5 093 | −18 853 | −36 524 | −26 712 | −15 130 |
| EBITDA | −3 832 | −11 268 | −49 961 | −20 012 | −8 554 |
| Depreciation & amort. | −931 | −1 201 | −1 621 | −1 504 | −1 128 |
| EBIT | −4 763 | −12 469 | −51 582 | −21 516 | −9 682 |
| Net financials | −6 | −69 | 97 | −964 | −874 |
| Profit before tax | −4 769 | −12 537 | −51 485 | −22 481 | −10 556 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −4 769 | −12 537 | −51 485 | −22 481 | −10 556 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 25 628 | 16 431 | 23 448 | 15 623 | 8 511 |
| Equity | 16 110 | 4 841 | 9 312 | −13 168 | 3 311 |
| Long-term debt | 1 493 | 1 493 | 900 | 900 | 900 |
| Short-term debt | 7 603 | 9 637 | 12 929 | 27 791 | 4 290 |
| Total debt | 9 095 | 11 130 | 13 829 | 28 691 | 5 190 |
EBITDA margin
-37.9%
This company
15.8%
Market median
-340% vs market
20202024
Equity ratio
38.9%
This company
38.2%
Market median
+2% vs market
20202024
Return on equity
-318.8%
This company
18.4%
Market median
-1833% vs market
20202024
Net profit margin
-46.8%
This company
8.1%
Market median
-678% vs market
20202024
Asset turnover
2.65×
This company
1.12×
Market median
+137% vs market
20202024
Debt / equity
1.57×
This company
0.62×
Market median
-153% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
NS Chief Executive Officer | Chief Executive Officer | 2017 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (9) | ||
| Chairman | 2022 | |
| Chairman | 2025 | |
| Board of Directors | 2022 | |
| Chairman | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2025 | |
| Former (4) | ||
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2022 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 27.8% | 27.8% | 2023 | |
| Individual | 26.95% | 26.95% | 2022 | |
Schibsted Tillväxtmedier Ab | Company | 26.95% | 26.95% | 2023 |
| Company | 8.61% | 8.61% | 2023 | |
| Company | 8.61% | 8.61% | 2023 | |
| Company | 6.19% | 6.19% | 2023 | |
| Company | 5.25% | 5.25% | 2023 | |
| Company | 4.87% | 4.87% | 2023 | |
| Company | 1.92% | 1.92% | 2023 | |
| Company | 1.82% | 1.82% | 2023 | |
| Company | 1.79% | 1.79% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HJEMMELEGENE AS 
HJEMMELEGENE BHT ASBoard members of HJEMMELEGENE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nicolai Skarsgård | Chief Executive Officer | 0 companies |
| Raman Bhatnagar | Chairman | 0 companies |
| Pål Lillebø | Chairman | 0 companies |
| Christian Horn-Hanssen | Board of Directors | 0 companies |
| Knut Johan Arnholdt | Chairman | 0 companies |
| Tarje Holskil | Board of Directors | 0 companies |
| Vegard Aakre Vik | Board of Directors | 0 companies |
| Rune Spikseth | Board of Directors | 0 companies |
| Andre Bregård | Board of Directors | 0 companies |
| Just Bing Ebbesen | Board of Directors | 0 companies |
| Kristian Fredrik Kværner Huseby | Board of Directors | 0 companies |
| Johan Max Otto Gustav Alwén | Board of Directors | 0 companies |
| Trond Røsdal | Board of Directors | 0 companies |
| Christian Horn Hanssen | Board of Directors | 0 companies |